Is Bicara Therapeutics Stock a Good Investment?
Bicara Therapeutics Investment Advice | BCAX |
- Examine Bicara Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bicara Therapeutics' leadership team and their track record. Good management can help Bicara Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Bicara Therapeutics' business and its evolving consumer preferences.
- Compare Bicara Therapeutics' performance and market position to its competitors. Analyze how Bicara Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Bicara Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bicara Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bicara Therapeutics Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bicara Therapeutics Common is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bicara Therapeutics Stock
Researching Bicara Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 1.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bicara Therapeutics recorded a loss per share of 3.75. The entity had not issued any dividends in recent years.
To determine if Bicara Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bicara Therapeutics' research are outlined below:
| Bicara Therapeutics generated a negative expected return over the last 90 days | |
| Bicara Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (51.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bicara Therapeutics generates negative cash flow from operations | |
| Bicara Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 |
Bicara Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Bicara Therapeutics Analyst Ratings
Bicara Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Bicara Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Bicara Therapeutics' financials, market performance, and future outlook by experienced professionals. Bicara Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Bicara Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 900.58 M.Market Cap |
|
Bicara Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.21) | (0.20) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | 0.40 | 0.41 |
Determining Bicara Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Bicara Therapeutics is a good buy. For example, gross profit margin measures Bicara Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bicara Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bicara Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bicara Therapeutics Common. Check Bicara Therapeutics' Beneish M Score to see the likelihood of Bicara Therapeutics' management manipulating its earnings.
Basic technical analysis of Bicara Stock
As of the 27th of March, Bicara Therapeutics shows the mean deviation of 3.7, and Risk Adjusted Performance of (0.03). Bicara Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bicara Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bicara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bicara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bicara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Meisner Lara over a week ago Acquisition by Meisner Lara of 79146 shares of Bicara Therapeutics at 5.45 subject to Rule 16b-3 | ||
Meisner Lara over a week ago Disposition of 30620 shares by Meisner Lara of Bicara Therapeutics at 13.2434 subject to Rule 16b-3 | ||
Cohlhepp Ryan over two weeks ago Disposition of 20836 shares by Cohlhepp Ryan of Bicara Therapeutics at 4.1 subject to Rule 16b-3 | ||
Ra Capital Management, L.p. over three months ago Acquisition by Ra Capital Management, L.p. of 1680520 shares of Bicara Therapeutics at 18.0 subject to Rule 16b-3 | ||
Tpg Gp A, Llc over six months ago Discretionary transaction by Tpg Gp A, Llc of 1960425 shares of Bicara Therapeutics subject to Rule 16b-3 |
Bicara Therapeutics' Outstanding Corporate Bonds
Bicara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bicara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bicara bonds can be classified according to their maturity, which is the date when Bicara Therapeutics Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| BHP 642 01 MAR 26 Corp BondUS055450AH34 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BGGRP 5125 15 OCT 41 Corp BondUS05541VAF31 | View | |
| BHP 49 28 FEB 33 Corp BondUS055451BA54 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Bicara Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bicara Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 3.7 | |||
| Coefficient Of Variation | (2,127) | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.52 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 20.05 | |||
| Value At Risk | (7.85) | |||
| Potential Upside | 7.64 | |||
| Skewness | 0.0549 | |||
| Kurtosis | (0.46) |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 3.7 | |||
| Coefficient Of Variation | (2,127) | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.52 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 20.05 | |||
| Value At Risk | (7.85) | |||
| Potential Upside | 7.64 | |||
| Skewness | 0.0549 | |||
| Kurtosis | (0.46) |
Consider Bicara Therapeutics' intraday indicators
Bicara Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bicara Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Bicara Therapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of March 2025 Other Reports | ViewVerify | |
| 12th of February 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Bicara Stock media impact
Far too much social signal, news, headlines, and media speculation about Bicara Therapeutics that are available to investors today. That information is available publicly through Bicara media outlets and privately through word of mouth or via Bicara internal channels. However, regardless of the origin, that massive amount of Bicara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bicara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bicara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bicara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bicara Therapeutics alpha.
Bicara Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bicara Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bicara Therapeutics Corporate Management
| Angela Windt | VP Affairs | Profile | |
| Rachel Salazar | SVP Operations | Profile | |
| MD MBA | Senior Affairs | Profile | |
| Lara JD | Chief Secretary | Profile | |
| JeanPaul Rodrique | Senior Assurance | Profile | |
| Sathish Hasige | Senior Chain | Profile |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.